HUP0200602A3 - Pharmaceutical compositions containing a combination of a 5-ht reuptake inhibitor and a h5-ht1b antagonist or partial agonist and their use - Google Patents
Pharmaceutical compositions containing a combination of a 5-ht reuptake inhibitor and a h5-ht1b antagonist or partial agonist and their useInfo
- Publication number
- HUP0200602A3 HUP0200602A3 HU0200602A HUP0200602A HUP0200602A3 HU P0200602 A3 HUP0200602 A3 HU P0200602A3 HU 0200602 A HU0200602 A HU 0200602A HU P0200602 A HUP0200602 A HU P0200602A HU P0200602 A3 HUP0200602 A3 HU P0200602A3
- Authority
- HU
- Hungary
- Prior art keywords
- combination
- pharmaceutical compositions
- compositions containing
- reuptake inhibitor
- partial agonist
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000004031 partial agonist Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Replacement Of Web Rolls (AREA)
- Winding, Rewinding, Material Storage Devices (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9703375A SE9703375D0 (sv) | 1997-09-18 | 1997-09-18 | A new combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0200602A2 HUP0200602A2 (hu) | 2002-07-29 |
| HUP0200602A3 true HUP0200602A3 (en) | 2003-04-28 |
Family
ID=20408295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0200602A HUP0200602A3 (en) | 1997-09-18 | 1998-09-09 | Pharmaceutical compositions containing a combination of a 5-ht reuptake inhibitor and a h5-ht1b antagonist or partial agonist and their use |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6159971A (enExample) |
| EP (1) | EP1014985B1 (enExample) |
| JP (1) | JP2001516718A (enExample) |
| KR (1) | KR20010024076A (enExample) |
| CN (1) | CN1195519C (enExample) |
| AR (1) | AR015448A1 (enExample) |
| AT (1) | ATE240733T1 (enExample) |
| AU (1) | AU752722B2 (enExample) |
| BR (1) | BR9812088A (enExample) |
| CA (1) | CA2302382A1 (enExample) |
| DE (1) | DE69814882T2 (enExample) |
| DK (1) | DK1014985T3 (enExample) |
| EE (1) | EE04141B1 (enExample) |
| ES (1) | ES2200370T3 (enExample) |
| HU (1) | HUP0200602A3 (enExample) |
| IL (1) | IL134776A0 (enExample) |
| IS (1) | IS5406A (enExample) |
| MY (1) | MY116280A (enExample) |
| NO (1) | NO20001399L (enExample) |
| NZ (1) | NZ503171A (enExample) |
| PL (1) | PL339371A1 (enExample) |
| PT (1) | PT1014985E (enExample) |
| RU (1) | RU2214824C2 (enExample) |
| SE (1) | SE9703375D0 (enExample) |
| SK (1) | SK2852000A3 (enExample) |
| TR (1) | TR200000727T2 (enExample) |
| TW (1) | TW589183B (enExample) |
| WO (1) | WO1999013877A1 (enExample) |
| ZA (1) | ZA987817B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9601110D0 (sv) | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| UA77650C2 (en) | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| WO2002066454A1 (fr) * | 2001-02-21 | 2002-08-29 | Sankyo Company, Limited | Derives de chromene |
| US20040198809A1 (en) * | 2001-05-01 | 2004-10-07 | Connie Sanchez | Use of enantiomeric pure escitalopram |
| ES2323451T7 (es) * | 2001-07-20 | 2011-08-01 | Psychogenics Inc. | Tratamiento para el trastorno de hiperactividad con deficit de atencion. |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| SE0203778D0 (sv) * | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | A new oral immediated release dosage form |
| AR047553A1 (es) | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
| KR100511288B1 (ko) * | 2003-11-14 | 2005-08-31 | 엘지전자 주식회사 | 4대의 압축기를 구비한 공기조화기의 실외기 |
| WO2006091725A1 (en) * | 2005-02-23 | 2006-08-31 | The Silvan S. Tomkins Institute | Treatment of anhedonia |
| EP1912650B8 (en) | 2005-08-03 | 2017-10-18 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
| FR2890862B1 (fr) * | 2005-09-19 | 2008-01-25 | Sanofi Aventis Sa | Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique. |
| JP2009513604A (ja) | 2005-10-29 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体 |
| US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
| US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
| RU2455981C2 (ru) * | 2006-06-16 | 2012-07-20 | Теракос, Инк. | Лечение ожирения антагонистами мускаринового рецептора м1 |
| ATE456369T1 (de) | 2006-06-30 | 2010-02-15 | Boehringer Ingelheim Int | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| EA200900264A1 (ru) | 2006-08-14 | 2009-08-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Композиции флибансерина и способ их приготовления |
| JP5220746B2 (ja) | 2006-08-25 | 2013-06-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 制御放出システム及びその製造方法 |
| CL2008002693A1 (es) | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9119932D0 (en) * | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| DE69232003T2 (de) * | 1991-09-18 | 2002-04-25 | Glaxo Group Ltd., Greenford | Benzanilidderivate als 5-HT1D-Antagonisten |
| SE9601110D0 (sv) * | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| SE9703374D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
-
1997
- 1997-09-18 SE SE9703375A patent/SE9703375D0/xx unknown
-
1998
- 1998-08-27 ZA ZA987817A patent/ZA987817B/xx unknown
- 1998-08-29 TW TW087114344A patent/TW589183B/zh not_active IP Right Cessation
- 1998-09-09 PL PL98339371A patent/PL339371A1/xx unknown
- 1998-09-09 NZ NZ503171A patent/NZ503171A/en unknown
- 1998-09-09 WO PCT/SE1998/001601 patent/WO1999013877A1/en not_active Ceased
- 1998-09-09 KR KR1020007002822A patent/KR20010024076A/ko not_active Ceased
- 1998-09-09 AT AT98944375T patent/ATE240733T1/de not_active IP Right Cessation
- 1998-09-09 CN CNB98811206XA patent/CN1195519C/zh not_active Expired - Fee Related
- 1998-09-09 ES ES98944375T patent/ES2200370T3/es not_active Expired - Lifetime
- 1998-09-09 IL IL13477698A patent/IL134776A0/xx unknown
- 1998-09-09 BR BR9812088-3A patent/BR9812088A/pt not_active IP Right Cessation
- 1998-09-09 US US09/171,580 patent/US6159971A/en not_active Expired - Fee Related
- 1998-09-09 TR TR2000/00727T patent/TR200000727T2/xx unknown
- 1998-09-09 HU HU0200602A patent/HUP0200602A3/hu unknown
- 1998-09-09 RU RU2000109563/14A patent/RU2214824C2/ru not_active IP Right Cessation
- 1998-09-09 EP EP98944375A patent/EP1014985B1/en not_active Expired - Lifetime
- 1998-09-09 DE DE69814882T patent/DE69814882T2/de not_active Expired - Fee Related
- 1998-09-09 EE EEP200000141A patent/EE04141B1/xx not_active IP Right Cessation
- 1998-09-09 CA CA002302382A patent/CA2302382A1/en not_active Abandoned
- 1998-09-09 PT PT98944375T patent/PT1014985E/pt unknown
- 1998-09-09 SK SK285-2000A patent/SK2852000A3/sk unknown
- 1998-09-09 JP JP2000511499A patent/JP2001516718A/ja active Pending
- 1998-09-09 AU AU91930/98A patent/AU752722B2/en not_active Ceased
- 1998-09-09 DK DK98944375T patent/DK1014985T3/da active
- 1998-09-16 MY MYPI98004225A patent/MY116280A/en unknown
- 1998-09-17 AR ARP980104634A patent/AR015448A1/es unknown
-
2000
- 2000-03-15 IS IS5406A patent/IS5406A/is unknown
- 2000-03-17 NO NO20001399A patent/NO20001399L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0200602A3 (en) | Pharmaceutical compositions containing a combination of a 5-ht reuptake inhibitor and a h5-ht1b antagonist or partial agonist and their use | |
| HUP0102658A3 (en) | Pharmaceutical composition containing opioid agonist and antagonist combination | |
| HUP9702036A3 (en) | Inhibitors of leucocita-adhesion and wla-4-antagonists and pharmaceutical compositions containing them | |
| HUP9702035A3 (en) | Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them | |
| HUP9702034A3 (en) | Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them | |
| HUP0400475A3 (en) | Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof | |
| HUP9701068A3 (en) | Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
| HUP0203586A3 (en) | The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist | |
| DK1454901T3 (da) | Farmaceutiske sammensætninger omfattende tachykininantagonister og en serotoningenoptagelseshæmmer | |
| ZA987800B (en) | Pharmaceutical composition of meloxicam | |
| HUP0302385A3 (en) | New multicyclic compounds and their use and pharmaceutical compositions containing them | |
| HUP0101999A3 (en) | 4-hydroxyquinoline-3-carboxamides and hydrazides use of them and pharmaceutical compositions containing them | |
| IL154057A0 (en) | New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation | |
| HUP9801227A3 (en) | Pharmaceutical compositions comprising monoamine oxidase b inhibitors and their use | |
| HUP0004008A3 (en) | Polymorphic form of a morpholine derivative having tachykinin receptor antagonist activity and pharmaceutical compositions containing the same | |
| IL115771A (en) | Apolipoprotein-B synthesis inhibitors their preparation and pharmaceutical compositions containing them | |
| IL134775A0 (en) | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST | |
| HU9503624D0 (en) | Use of p antagonist in pharmaceutical compositions | |
| AU2001225663A1 (en) | A composition comprising a combination of receptor agonists and antagonists | |
| HUP0400654A3 (en) | Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them | |
| HUP0102025A3 (en) | Derivatives of 1,3,4-oxadiazolone, pharmaceutical compositions containing them and their use | |
| HUP0101733A3 (en) | Pharmaceutical compositions containing sulfonyl-dipeptides and their use | |
| HUP0003832A3 (en) | Azeotropic or pseudo-azeotropic compositions and use of these compositions | |
| EP1028958A4 (en) | ARYLPIPERAZINES ACTING AS SEROTONIN REABSORPTION INHIBITORS AND AS 5-HT1D ALPHA ANTAGONISTS | |
| HUP0202753A3 (en) | Pharmaceutical compositions containing novel combination of loteprednol and b2-adrenoceptor agonists and their use |